DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Pinatuzumab vedotin
Pinatuzumab vedotin
Polatuzumab Vedotin - R/R DLBCL RG7769 PD1-TIM3 Bimab - Solid Tumors NSCLC RG7446 Tecentriq – Her2-Pos
Predictive QSAR Tools to Aid in Early Process Development of Monoclonal Antibodies
Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
University of Groningen PET Imaging and in Silico Analyses to Support
Ep 3178848 A1
(INN) for Biological and Biotechnological Substances
761121Orig1s000
Polatuzumab Vedotin -1L DLBCL RG7601 Venclexta + LDAC – 1L AML
NSCLC (Update) • Cotellic + Zelboraf: Phase III 1L Melanoma (Cobrim), Overall Survival
IMSN Letter on Antibody-Drug Conjugates 2015 03 23
Stembook 2018.Pdf
Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
(INN) for Biological and Biotechnological Substances
2.03.502 Monoclonal Antibodies for the Treatment of Lymphoma
Pipeline Summary
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Top View
Antibody Drug Conjugates (ADC)
Printemps Hematologie VF.Pdf
Roche Investor Presentation
Prescrire's Contribution to the WHO Consultation on List 112 Of
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Final Results of a Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin
Prescrire Contribution to Proposed INN List
IMSN Open Letter on Antibody-Drug Conjugate 2151012
Oncology Drugs in the Pipeline
Anti-CD22 and Anti-CD79B Antibody Drug Conjugates Are Active in Different Molecular Diffuse Large B-Cell Lymphoma Subtypes
Patient Selection Strategies to Maximize Therapeutic Index Of
QSAR Model Development for Early Stage Screening of Monoclonal Antibody Therapeutics to Facilitate Rapid Developability
NHL: How Will Emerging Therapies Change the Treatment Paradigm? Pier Luigi Zinzani Institute of Hematology «L
(INN) for Biological and Biotechnological Substances
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances" WHO/EMP/RHT/TSN/2013.1
Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy
Current Status of Marine-Derived Compounds As Warheads in Anti-Tumor Drug Candidates
Phase I Study of the Anti-CD22 Antibody–Drug Conjugate
Assessment Report: Polivy
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
(12) Patent Application Publication (10) Pub. No.: US 2015/0374790 A1 Liu Et Al